40
Participants
Start Date
September 30, 2007
Primary Completion Date
May 31, 2011
Study Completion Date
May 31, 2011
FTC/TDF
Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
Hepatitis B Immunoglobulin (HBIg)
HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
New York
New York
Atlanta
Chicago
Los Angeles
San Francisco
San Francisco
Lead Sponsor
Gilead Sciences
INDUSTRY